AngioDynamics Launches the Innovative RECOVER-AV Clinical Trial
AngioDynamics, Inc. (NASDAQ: ANGO), known as a pioneer in medical technology, has taken a significant step forward by initiating the RECOVER-AV trial. This multicenter, multinational, single-arm clinical study is set to investigate the safety, effectiveness, and long-term functional outcomes of the AlphaVac F18?? System for treating acute pulmonary embolism (PE). This trial reflects AngioDynamics’ dedication to finding solutions that restore healthy blood flow and improve cancer treatment options for patients around the globe.
Objectives of the RECOVER-AV Trial
The RECOVER-AV trial primarily aims to evaluate the AlphaVac system's performance as a viable treatment option for patients suffering from intermediate-risk acute pulmonary embolism. This important clinical evaluation is part of AngioDynamics’ strategy to introduce the system into the European market, particularly in light of a growing number of PE cases. Through this study, AngioDynamics hopes to provide solid clinical evidence demonstrating the device’s effectiveness.
This critical trial follows the earlier APEX-AV study, which showed that the AlphaVac F18?? System is not only safe but also significantly enhances right ventricular function while reducing clot burden, ultimately improving patient outcomes. Findings from the RECOVER-AV trial are expected to bolster the existing body of literature concerning treatment approaches for PE.
Details of the Clinical Study
The RECOVER-AV trial plans to recruit patients diagnosed with intermediate-risk acute PE across roughly 20 hospital sites in Europe, emphasizing a collaborative international effort. The primary efficacy endpoint will involve monitoring changes in the right ventricular/left ventricular (RV/LV) ratio from baseline metrics 48 hours after the procedure. Additionally, the study will keep track of any major adverse events (MAEs), focusing specifically on device-related fatalities or major bleeding incidents within a week. To ensure comprehensive evaluation, patients will also be assessed for functional outcomes after 30 days, six months, and one year.
Tackling the Challenge of Pulmonary Embolism
Statistics indicate that close to 435,000 PE cases are reported each year across six major European Union countries. Research has highlighted that the incidence of PE is considerably higher in Europe compared to the United States, where patients arriving at emergency departments often face more severe conditions and poor outcomes. By launching this clinical trial, AngioDynamics aims to clarify the efficacy of treatments and enhance the management of acute PE in the relevant regions.
Laura Piccinini, the Senior Vice President and General Manager of Endovascular Therapies and International at AngioDynamics, expressed enthusiasm about the trial’s commencement. “We’re excited to evaluate how well the AlphaVac F18?? System performs in treating intermediate-risk pulmonary embolisms. Our collaborative partnerships with clinical associates reflect our commitment to producing meaningful clinical evidence globally,” she said. This initiative is set to further establish AngioDynamics as a leader in creating innovative medical solutions.
Regulatory Approval and Future Perspectives
In line with its commitment to safe and effective treatment alternatives, AngioDynamics received CE Mark approval for the AlphaVac F18?? System earlier this year. This certification facilitates the device’s use in non-surgical thrombus removal from pulmonary arteries for PE treatment. With this development, AngioDynamics is positioned to expand its presence in the European market, addressing an urgent demand for improved treatment protocols in managing pulmonary embolism.
Leadership and Scientific Direction
The RECOVER-AV trial is being spearheaded by co-Principal Investigators Erik Klok, MD, and Andrew Sharp, MD, both respected figures in their areas of expertise. Their efforts are bolstered by a renowned Scientific Advisory Board, composed of specialists in pulmonary embolism and associated medical fields. This structure helps ensure that the study adheres to high standards of excellence and relevance in its findings.
With robust support from prominent specialists throughout Europe, this trial aims to establish effective protocols that could ultimately enhance the clinical landscape of pulmonary embolism treatments.
About AngioDynamics, Inc.
AngioDynamics stands out in the medical technology industry, dedicated to improving patient outcomes by focusing on advancements in vascular health and cancer treatment. Through their innovative medical devices and technologies, the company endeavors to address critical patient needs and is frequently selected by skilled physicians in expanding healthcare markets.
Frequently Asked Questions
What is the RECOVER-AV clinical trial about?
The RECOVER-AV clinical trial is focused on assessing the safety and effectiveness of the AlphaVac F18?? System in treating acute pulmonary embolism.
Who is overseeing the RECOVER-AV trial?
The trial is managed by co-Principal Investigators Erik Klok, MD, and Andrew Sharp, MD, with guidance from an international Scientific Advisory Board.
What key endpoints does the trial aim to achieve?
The primary endpoints include a decrease in the RV/LV ratio from baseline and surveillance of major adverse events.
Where will the trial be conducted?
The trial will enroll participants from approximately 20 hospital sites across Europe.
What makes the AlphaVac F18?? System important?
The AlphaVac F18?? System is designed for the non-surgical removal of thrombi from pulmonary arteries, improving treatment options for patients suffering from acute pulmonary embolism.
